Approved indication:

• No FDA-approved post-transplant nephrology indication – recommended as a potential treatment option during post-transplant glomerulonephritis recurrence

MOA:

• Blood filtration process that helps reduce fibrinogen, immune complexes, complement components, and anti-glomerular basement membrane antibodies³²